Holen Sie sich die Stockscreener-App
12.31
4.50%
-0.58
Schlusskurs vom Vortag:
$12.89
Offen:
$13.01
24-Stunden-Volumen:
683.56K
Relative Volume:
0.80
Marktkapitalisierung:
$643.52M
Einnahmen:
$88.24M
Nettoeinkommen (Verlust:
$-160.90M
KGV:
-4.6205
EPS:
-2.6642
Netto-Cashflow:
$-129.35M
1W Leistung:
-5.31%
1M Leistung:
+41.17%
6M Leistung:
+64.13%
1J Leistung:
+182.99%
1-Tages-Spanne:
$11.57
$13.01
1-Wochen-Bereich:
$11.57
$13.39
52-Wochen-Spanne:
$4.11
$14.00
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Firmenname
4 D Molecular Therapeutics Inc
Sektor
Branche
Telefon
(510) 505-2680
Adresse
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
12.31 | 643.52M | 88.24M | -160.90M | -129.35M | -2.6642 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2025-11-07 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Underweight |
| 2024-09-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | Eingeleitet | Barclays | Overweight |
| 2024-02-07 | Fortgesetzt | Goldman | Buy |
| 2023-10-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-18 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-15 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-12 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | Eingeleitet | Jefferies | Buy |
| 2022-01-04 | Eingeleitet | SVB Leerink | Outperform |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Evercore ISI | Outperform |
| 2021-01-05 | Eingeleitet | Goldman | Neutral |
Alle ansehen
4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten
FDMT (FDMT) insider plans Form 144 Class A share sale and lists prior trades - Stock Titan
Form 144 4D Molecular Therapeutics For: 9 July By Investing.com - Investing.com Canada
David Kirn sells Class A shares for FDMT (FDMT) in June 2026 - Stock Titan
FDMT4D Molecular Therapeutics Inc Revenue Breakdown - Finviz
Price to earnings forward of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
FDMT (NASDAQ: FDMT) CLO sells 6,566 shares, exercises options under 10b5-1 plan - Stock Titan
Form 144 4D Molecular Therapeutics For: 30 June By Investing.com - Investing.com Canada
FDMT (NASDAQ: FDMT) insider 10b5-1 sale of 9,810 shares for $117,720 - Stock Titan
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - The Manila Times
4DMT to present 2-year PRISM trial follow-up at retina meeting - Stock Titan
H.C. Wainwright reiterates Buy on 4D Molecular stock on trial progress By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
4D Molecular Therapeutics Shares Rise After New Credit Facility - Moomoo
4D Molecular Therapeutics secures $200M credit facility - Investing.com
4D Molecular (FDMT) Completes Enrollment for Phase 3 Clinical Tr - GuruFocus
4D Molecular Therapeutics Completes Enrollment for 4Front-2 Global Phase 3 Clinical Trial of 4D-150 in Wet Amd - marketscreener.com
4D Molecular Therapeutics Secures Strategic Credit Facility for Up to $200 Million from Hercules Capital - marketscreener.com
4D Molecular Therapeutics secures $200M credit facility By Investing.com - Investing.com Australia
4D Molecular Therapeutics Secures $200 Million Loan Facility - TipRanks
4D Molecular Therapeutics Secures Up to $200 Million Term Loan Facility From Hercules Capital - TradingView
4D Molecular Therapeutics (FDMT) signs up to $200M secured loan with Hercules - Stock Titan
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - The Manila Times
4DMT finishes Phase 3 enrollment for wet AMD gene therapy trial - Stock Titan
4D Molecular Therapeutics, Inc. Actuals & Estimates (NASDAQ:FDMT) - TradingView
4D Molecular Therapeutics (FDMT) Inches Higher as Biotech Sector Watches Key LevelsEntry Point Alerts - dars.gov.et
Strength seen in 4D Molecular Therapeutics (FDMT): Can its 7.9% jump turn into more strength? - MSN
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock - Investing.com UK
Form 4 4D Molecular Therapeutics Inc For: 25 June By Investing.com - Investing.com Nigeria
4d molecular therapeutics CLO Scott Bizily sells $117,720 in stock By Investing.com - Investing.com Nigeria
4D Molecular (NASDAQ: FDMT) CLO exercises options, sells 9,810 shares at $12 - Stock Titan
FDMT Forecast — Price Target — Prediction for 2027 - TradingView
Retinitis Pigmentosa Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics, 4D Molecular Therap - Barchart.com
Form 144 4D Molecular Therapeutics For: 23 June By Investing.com - Investing.com South Africa
4d molecular therapeutics CEO David Kirn sells $1.2m in stock - Investing.com UK
4d molecular therapeutics CEO David Kirn sells $1.2m in stock By Investing.com - Investing.com India
Form 4 4D Molecular Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Insider Sell Alert: David Kirn Sells 114,746 Shares of 4D Molecu - GuruFocus
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Insider David Kirn sells 114,746 4D Molecular Therapeutics (FDMT) shares - Stock Titan
4D Molecular Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kirn David - Moomoo
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Yahoo Finance
4D Molecular Therapeutics, Inc. announced that it expects to receive $200 million in funding - marketscreener.com
Form 144 4D Molecular Therapeutics For: 22 June By Investing.com - Investing.com Nigeria
David Kirn reports sale of 1,922 FDMT shares via Goldman Sachs (FDMT) - Stock Titan
4D Molecular Therapeutics Stockholders Back Directors and Governance - TipRanks
4D Molecular Therapeutics stockholders elect directors and approve proposals at annual meeting - Investing.com Australia
Form 8K 4D Molecular Therapeutics Inc For: 22 June By Investing.com - Investing.com Nigeria
Finanzdaten der 4 D Molecular Therapeutics Inc-Aktie (FDMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):